Decision: Favourable
Study Title:
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)
NREC Code:
22-NREC-CT-026
Decision:
Favourable
Meeting Date:
23/02/2022
Study Type:
CT application
Principal Investigator:
Dr Anne Fortune
PI Institution:
MMUH
Sponsor:
Loxo Oncology Inc.